BRPI1000030A2 - métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição. - Google Patents

métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.

Info

Publication number
BRPI1000030A2
BRPI1000030A2 BRPI1000030A BRPI1000030A BRPI1000030A2 BR PI1000030 A2 BRPI1000030 A2 BR PI1000030A2 BR PI1000030 A BRPI1000030 A BR PI1000030A BR PI1000030 A BRPI1000030 A BR PI1000030A BR PI1000030 A2 BRPI1000030 A2 BR PI1000030A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treating multiple
patient
composition
methods
Prior art date
Application number
BRPI1000030A
Other languages
English (en)
Portuguese (pt)
Inventor
R Blight Andrew
Cohen Ron
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1000030(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BRPI1000030A2 publication Critical patent/BRPI1000030A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI1000030A 2009-02-11 2010-02-11 métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição. BRPI1000030A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28
PCT/US2010/023969 WO2010093838A1 (en) 2009-02-11 2010-02-11 Compostions and methods for using aminopyridines

Publications (1)

Publication Number Publication Date
BRPI1000030A2 true BRPI1000030A2 (pt) 2018-02-14

Family

ID=42562065

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1000031A BRPI1000031A2 (pt) 2009-02-11 2010-02-11 métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição
BRPI1000030A BRPI1000030A2 (pt) 2009-02-11 2010-02-11 métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI1000031A BRPI1000031A2 (pt) 2009-02-11 2010-02-11 métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição

Country Status (22)

Country Link
US (3) US20120029035A1 (OSRAM)
JP (1) JP2012517449A (OSRAM)
KR (3) KR20170034452A (OSRAM)
CN (2) CN101896182A (OSRAM)
AR (1) AR075413A1 (OSRAM)
AU (2) AU2010213663A1 (OSRAM)
BR (2) BRPI1000031A2 (OSRAM)
CA (1) CA2751581A1 (OSRAM)
CL (1) CL2011001927A1 (OSRAM)
CO (1) CO6440534A2 (OSRAM)
EA (1) EA022755B1 (OSRAM)
EC (1) ECSP11011311A (OSRAM)
IL (1) IL214500A0 (OSRAM)
MX (1) MX2011008485A (OSRAM)
NI (1) NI201100155A (OSRAM)
NZ (1) NZ595046A (OSRAM)
PE (1) PE20120791A1 (OSRAM)
SG (2) SG173641A1 (OSRAM)
TN (1) TN2011000403A1 (OSRAM)
TW (2) TW201032809A (OSRAM)
UY (2) UY32444A (OSRAM)
WO (2) WO2010093839A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
EP2814492A1 (en) * 2012-02-13 2014-12-24 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2015118529A1 (en) * 2014-02-04 2015-08-13 Optimata Ltd. Method and system for prediction of medical treatment effect
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
AU2010213663A1 (en) 2011-09-29
CN102046174A (zh) 2011-05-04
SG10201609184PA (en) 2016-12-29
WO2010093839A1 (en) 2010-08-19
AU2016219650B2 (en) 2018-05-10
WO2010093838A1 (en) 2010-08-19
PE20120791A1 (es) 2012-07-08
NI201100155A (es) 2012-02-16
ECSP11011311A (es) 2011-10-31
UY32444A (es) 2010-09-30
KR20170034452A (ko) 2017-03-28
CO6440534A2 (es) 2012-05-15
IL214500A0 (en) 2011-09-27
TW201034665A (en) 2010-10-01
UY32445A (es) 2010-09-30
CA2751581A1 (en) 2010-08-19
KR20120000560A (ko) 2012-01-02
BRPI1000031A2 (pt) 2018-02-14
US20170319562A1 (en) 2017-11-09
US20150313886A1 (en) 2015-11-05
AR075413A1 (es) 2011-03-30
NZ595046A (en) 2013-10-25
EA201171043A1 (ru) 2012-02-28
AU2016219650A1 (en) 2016-09-15
US20120029035A1 (en) 2012-02-02
CN101896182A (zh) 2010-11-24
TW201032809A (en) 2010-09-16
CL2011001927A1 (es) 2012-07-20
EA022755B1 (ru) 2016-02-29
JP2012517449A (ja) 2012-08-02
TN2011000403A1 (en) 2013-03-27
MX2011008485A (es) 2011-11-04
AU2016219650C1 (en) 2018-08-23
SG173641A1 (en) 2011-09-29
KR20180114250A (ko) 2018-10-17

Similar Documents

Publication Publication Date Title
BRPI1000030A2 (pt) métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
IT1400425B1 (it) Modified snrnas for use in therapy.
BR112012002143A2 (pt) agentes terapêuticos para redução dos níveis de hormônio da paratieóide.
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI1009598A2 (pt) aparelho para redução do ronco, método para redução do ronco e programa de computador para redução do ronco
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0907036A2 (pt) Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BR112013008957A2 (pt) composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
DE112010002714A5 (de) Polymere enthaltend substituierte anthracenyleinheiten, blends enthaltend diese polymere sowie vorrichtungen enthaltend diese polymere oder blends
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
LT2451482T (lt) Kombinuota terapija, skirta diabeto gydymui
BRPI0811844A2 (pt) Composto, e, método para tratar um paciente
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]